BioSpace News Archive

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights Offering”)

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities.

Perrigo Company plc announced that it has completed the acquisition of the branded over-the-counter rights to Prevacid®24HR.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia has received marketing approval of NERLYNX® in Singapore from the Health Sciences Authority, a statutory board under the Ministry of Health of the Singapore Government.

Elanco Animal Health Inc. announced Sara Place, Ph.D., has joined the company as Chief Sustainability Officer, emphasizing the company’s continued commitment to make an impact on societal challenges by improving the health of animals.

Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 178,500 shares of common stock to be distributed among eight new employees, with a grant date of December 2, 2019.

The National Stem Cell Foundation (NSCF) announced today that research teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services (CRS-19) mission, scheduled to launch December 4th from the Kennedy Space Center in Cape Canaveral, Florida.

Three Aspen Dental practice owners – Dr. Ashley Keen of Florida, Dr. Kurt Losier of Indiana, and Dr. Nathan Oakes of Maine - were recently named to the board of directors for the American Academy of Clear Aligners, news that was announced in fall issue of The Journal of the American Academy of Clear Aligners..

Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company’s rich dementia pipeline, including BAN2401, lemborexant and diagnostics methods, will be presented at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference, December 4-7, 2019 in San Diego.